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Abstract
Background: Oxaliplatin is an important drug used in the treatment of colorectal cancer. However, it frequently
causes severe acute and chronic peripheral neuropathies. We recently reported that repeated administration of
oxaliplatin induced cold hyperalgesia in the early phase and mechanical allodynia in the late phase in rats, and
that oxalate derived from oxaliplatin is involved in the cold hyperalgesia. In the present study, we examined the
effects of Ca
2+ channel blockers on oxaliplatin-induced cold hyperalgesia in rats.
Methods: Cold hyperalgesia was assessed by the acetone test. Oxaliplatin (4 mg/kg), sodium oxalate (1.3 mg/kg)
or vehicle was injected i.p. on days 1 and 2. Ca
2+ (diltiazem, nifedipine and ethosuximide) and Na
+ (mexiletine)
channel blockers were administered p.o. simultaneously with oxaliplatin or oxalate on days 1 and 2.
Results: Oxaliplatin (4 mg/kg) induced cold hyperalgesia and increased in the transient receptor potential
melastatin 8 (TRPM8) mRNA levels in the dorsal root ganglia (DRG). Furthermore, oxalate (1.3 mg/kg) significantly
induced the increase in TRPM8 protein in the DRG. Treatment with oxaliplatin and oxalate (500 μM for each) also
increased the TRPM8 mRNA levels and induced Ca
2+ influx and nuclear factor of activated T-cell (NFAT) nuclear
translocation in cultured DRG cells. These changes induced by oxalate were inhibited by nifedipine, diltiazem and
mexiletine. Interestingly, co-administration with nifedipine, diltiazem or mexiletine prevented the oxaliplatin-
induced cold hyperalgesia and increase in the TRPM8 mRNA levels in the DRG.
Conclusions: These data suggest that the L type Ca
2+ channels/NFAT/TRPM8 pathway is a downstream mediator
for oxaliplatin-induced cold hyperalgesia, and that Ca
2+ channel blockers have prophylactic potential for acute
neuropathy.
Background
Oxaliplatin, a platinum-based chemotherapeutic agent, is
widely used for treatment of colorectal cancer. However,
oxaliplatin frequently causes severe acute and chronic
peripheral neuropathies. Acute neuropathy is peculiar to
oxaliplatin and includes acral paresthesias enhanced by
exposure to cold [1-4]; the acute neuropathy is not
attributed to morphological damage to the nerve [5,6].
On the other hand, the chronic neuropathy is character-
ized by loss of sensory and motor function after long-
term oxaliplatin treatment, and it is similar to cisplatin-
induced neurological symptoms [4]. Recently, we
reported that repeated administration of oxaliplatin
induced cold hyperalgesia in the early phase and
mechanical allodynia in the late phase in rats [7]. Oxali-
platin is metabolized to oxalate and dichloro (1,2-diami-
nocyclohexane)platinum [Pt(dach)Cl2][ 8 ] .W er e p o r t e d
that oxalate and platinum metabolites were involved in
the cold hyperalgesia and mechanical allodynia, respec-
tively, and that intravenous pre-administration of Ca
2+
or Mg
2+ prevented the cold hyperalgesia but not
mechanical allodynia in rats [7].
Oxaliplatin-induced acute neuropathy is termed a
‘channelopathy’, as oxaliplatin and oxalate were shown
to modulate voltage-gated Na
+ and K
+ channels in
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increases the amplitude and duration of compound
action potentials interacting with voltage-gated Na
+
channels in rat sensory neurons [9]. Furthermore, oxali-
platin prolongs the duration of the A-fiber compound
action potential related to K
+ channels [12]. Thus, the
effect of oxaliplatin on Na
+ and K
+ channels is thought
to be involved in acute neuropathy [13].
Transient receptor potential (TRP) melastatin 8
(TRPM8), an ion channel that belongs to the TRP
family, is activated by innocuous cold (< 25°C) or
menthol [14,15]. Recently, an increase in TRPM8
mRNA levels was reported to be involved in the oxali-
platin-induced cold hyperalgesia in mice [16]. However,
the molecular mechanisms mediating the acute neuro-
pathy remain unclear. In the present study, we investi-
gated the involvement of voltage-gated Ca
2+ channels,
nuclear factor of activated T-cell (NFAT) and TRPM8
in the oxaliplatin-induced cold hyperalgesia, as up-regu-
lation of TRP channel 1 (TRPC1) expression is induced
by store-operated calcium (SOC) channel/NFAT, a tran-
scription factor regulated by the calcium signaling path-
way [17]. Furthermore, we investigated the effects of
Ca
2+ channel blockers on oxaliplatin-induced cold
hyperalgesia in rats.
Methods
Drugs and chemicals
Oxaliplatin (Elplat
®) was obtained from Yakult Co., Ltd.
(Tokyo, Japan). Sodium oxalate was provided by Wako
Pure Chemical Industries, Ltd. (Osaka, Japan). Mexile-
tine hydrochloride, nifedipine, diltiazem hydrochloride
and ethosuximide were purchased from Sigma-Aldrich,
Co. (MO, USA). Vivit was purchased from Calbiochem
(Darmstadt, Germany).
Animals
Male Sprague-Dawley rats weighing 200-250 g (Kyudo
Co., Saga, Japan) were used. Rats were housed in groups
of four to five per cage with lights on from 07:00 to
19:00 h. Animals had free access to food and water in
their home cages. All experiments were approved by the
Experimental Animal Care and Use Committee of
Kyushu University according to the National Institutes
of Health guidelines, and we followed the International
Association for the Study of Pain (IASP) Committee for
Research and Ethical Issues guidelines for animal
research [18].
Behavioral test
Cold hyperalgesia was assessed by the acetone test. Rats
were placed in a clear plastic box (20 × 17 × 13 cm)
with a wire mesh floor, and were allowed to habituate
for 30 min prior to testing. Fifty microliters of acetone
(Wako Pure Chemical Industries, Ltd.) was sprayed onto
the plantar skin of each hind paw 3 times with a Micro
Sprayer
® (Penn Century Inc., PA, USA), and the number
of withdrawal response was counted for 40 s from the
start of the acetone spray. Acetone tests were performed
on days 0 (pre), 3, 5, 8 and 15. Oxaliplatin and sodium
oxalate were dissolved in 5% glucose solution. Oxalipla-
tin (4 mg/kg), sodium oxalate (1.3 mg/kg) or vehicle
was injected i.p. on days 1 and 2. The vehicle-treated
rats were injected with 5% glucose solution. Mexiletine
hydrochloride, diltiazem and ethosuximide were dis-
solved in 5% saline. Nifedipine was suspended in 1%
carboxymethylcellulose sodium solution. Mexiletine, dil-
tiazem, nifedipine and ethosuximide were administered
p.o. simultaneously with oxaliplatin or oxalate on days 1
and 2.
Cell cultures
Male Sprague-Dawley rats (6 weeks old, Kyudo Co.)
were anesthetized with sodium pentobarbital, and the L
4-6 dorsal root ganglia (DRG) cells were removed and
primary cultured. Ganglia were incubated with 0.125%
(w/v) collagenase type 1 (Worthington Biochemical
Corp., NJ, USA) at 37°C for 90 min followed by incuba-
tion with 0.25% (w/v) trypsin-EDTA (Gibco BRL, CA,
USA) for 30 min. DRG cells were grown in Dulbecco’s
modified Eagle’s medium (MP Biomedicals, Inc., CA,
USA) with 2 mM L-glutamine and 10% FBS. The cells
were cultured at 37°C in air supplemented with 5% CO2
under humidified conditions. Oxaliplatin, oxalate, mexi-
letine, diltiazem and ethosuximide were dissolved in
medium. Nifedipine and vivit were dissolved in 0.2%
DMSO.
Measurement of intracellular Ca
2+ level
Cells were loaded with 5 μg/mL of Fura-2/AM (Dojindo
Lab., Kumamoto, Japan) and then incubated for 1 h at
37°C in HEPES buffer. The Fura-2/AM-loaded cells
were washed and placed in HEPES buffer. The intracel-
lular Ca
2+ levels were determined by emission fluores-
cence at 510 nm with excitation at 340 nm and 380 nm,
using FlexStation3 (Molecular Devices, Inc., CA, USA).
Immunostaining of NFATc4
Immunofluorescent staining for NFATc4 was performed
using a rabbit monoclonal antibody (Cell Signaling
Technology, Inc., MA, USA). Briefly, cells were cultured
on cover slips, and the cover slips then rinsed with ice-
cold phosphate-buffered saline and fixed with 4% (w/v)
ice-cold paraformaldehyde for 30 min at -20°C. The
NFATc4 antibody was diluted (1:100) with phosphate-
buffered saline (PBS) containing 5% (w/v) bovine serum
albumin and 0.1% Triton X-100. Cells were incubated
with diluted antibody solution overnight in a humidified
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were incubated at room temperature for 1 h with goat
anti-rabbit IgG (1:500 dilution in PBS) that was conju-
gated with Alexa Fluor
® 488 (Cell Signaling Technology,
Inc.). The nucleus was stained with 4’,6-Diamidino-2-
phenylindole dihydrochloride (DAPI; Dojindo Lab.).
NFATc4 and nuclear staining were visualized with a
fluorescence microscope (BX51; Olympus Corp., Tokyo,
Japan). The nuclear translocation of NFATc4 was calcu-
lated by comparing the ratio of nuclear NFATc4 immu-
nofluorescence/total NFATc4 immunofluorescence
using analysis software (Image J 1.36; Wayne Rasband,
National Institutes of Health, MD, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
mRNA was isolated from L4-6 DRG using PolyATtract
®
System 1000 (Promega, Corp., WI, USA). cDNA was
synthesized with PrimeScript
® 1st strand cDNA Synthesis
Kit (TaKaRa Bio, Inc., Shiga, Japan). PCR was performed
with Gene Taq (Nippon Gene, Co., Ltd., Tokyo, Japan).
The oligonucleotide primers for TRPM8 were designed
based on the sequences described by Ta and colleagues
[19]. The sequences of PCR primers were as follows:
TRPM8, 5’-GCC CAG TGA TGT GGA CAG TA-3’
(sense), 5’-GGA CTC ATT TCC CGA GAA GG-3’ (anti-
sense); glyceraldehyde-3-phosphate dehydrogenase
(G3PDH), 5’-YGC CTG CTT CAC CAC CTT-3’ (sense),
5’-TGC MTC CTG CAC CAC CAA CT-3’ (antisense)
(Sigma-Aldrich, Co.). Reactions were run for 35 cycles
with 95°C denaturing cycle (30 s), 62°C annealing cycle (1
min) and 72°C extension cycle (20 s) for TRPM8, or for
30 cycles with 94°C denaturing cycle (45 s), 53°C anneal-
ing cycle (45 s) and 72°C extension cycle (1.5 min) for
G3PDH. PCR products were resolved by electrophoresis
on a 4% agarose gel, and the DNA was visualized by
staining with ethidium bromide under ultraviolet irradia-
tion. The intensities of the PCR products were semi-
quantified densitometrically using Alpha Imager 2200
(Cell Biosciences, Inc., California, USA).
Western blotting
The L4-6 DRG was quickly removed on day 5. The tis-
sues were homogenized in a solubilization buffer con-
taining 20 mM Tris-HCl (pH7.4, 2 mM EDTA, 0.5 mM
E G T A ,1 0m MN a F ,1m MN a 3VO4,1m MP M S F ,0 . 3 2
M Sucrose, 2 mg/ml aprotinine, 2 mg/ml leupeptin),
and the homogenates were subjected to 4% SDS-PAGE,
and proteins were transferred electrophoretically to
PVDF membranes. The membranes were blocked in
Tris-buffered saline Tween-20 (TBST) containing 5%
BSA (Sigma-Aldrich) for an additional 1 h at room tem-
perature with agitation. The membrane was incubated
overnight at 4°C with rabbit polyclonal TRPM8 antibody
(Abcam, MA, USA) and then incubated for 1 h with
anti-rabbit IgG horseradish peroxidase (Jackson Immuno
Research Laboratories, Inc., PA, USA). The immunor-
eactivity was detected using Enhanced Chemilumines-
cence (Perkin Elmer, Massachusetts, USA).
Statistical analyses
Data are expressed as the mean ± SEM. Data were ana-
lyzed by the Student’s t-test or one-way analysis of var-
iance (ANOVA) followed by the Tukey-Kramer post
hoc test to determine differences between the groups. A
probability level of p < 0.05 was accepted as statistically
significant.
Results
Oxaliplatin increases cold hyperalgesia and TRPM8
expression in the DRG in rats
Administration of oxaliplatin (4 mg/kg, p.o., on days 1
and 2) significantly increased the number of withdrawal
responses to cold stimulation by acetone spray in rats
(Figure 1A, days 3, 5 and 8: p < 0.01). This increase in
withdrawal response had disappeared on day 15. On day
5, TRPM8 mRNA levels in the L4-6 DRG of oxaliplatin-
treated rats markedly increased as compared with those
of vehicle-treated rats (Figure 1B, p < 0.01). Also, oxa-
late treatment significantly induced the increase in
TRPM8 protein in the L4-6 DRG (Figure 1C, p < 0.05).
Oxaliplatin and oxalate increase the TRPM8 mRNA levels
in primary cultured DRG cells
Treatment with either oxaliplatin (Figure 1D) or oxalate
(Figure 1E) for 12 h markedly increased the TRPM8
mRNA levels in primary cultured DRG cells (p <0 . 0 5
for both).
Oxaliplatin and oxalate increase the intracellular Ca
2+
levels in primary cultured DRG cells
Oxaliplatin and oxalate (100-500 μM) induced dose-
dependent increases in intracellular Ca
2+ levels in cul-
tured DRG cells (Figure 2A, B). The percentages of
DRG neurons that responded to oxaliplatin and oxalate
were 69.2% and 64.0%, respectively. Nifedipine (30 μM),
an L type Ca
2+ channel blocker, and diltiazem (30 μM),
an L/T type Ca
2+ channel blocker, inhibited the increase
in intracellular Ca
2+ levels induced by oxalate (500 μM)
(Figure 2C, D). Mexiletine, a Na
+ channel blocker, also
dose-dependently inhibited the oxalate-induced increase
in intracellular Ca
2+ levels (Figure 2F). By contrast, etho-
suximide (1 mM), a T type Ca
2+ channel blocker, only
weakly attenuated the oxalate-induced increase in intra-
cellular Ca
2+ levels (Figure 2E).
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in primary cultured DRG cells
Treatment with oxaliplatin (500 μM) for 6 h induced
NFAT nuclear translocation (Figure 3A, B, 6 h: p <
0.01). Similarly, 500 μM oxalate caused NFAT nuclear
translocation (Figure 3C, D, 6 h: p < 0.01). Mexiletine (1
mM), nifedipine (30 μM) and diltiazem (30 μM) com-
pletely blocked the oxalate-induced NFAT nuclear
translocation (500 μM) (Figure 3E, F, p < 0.01).
Similarly, vivit (2 μM), a selective NFAT inhibitor, com-
pletely blocked the oxalate-induced NFAT nuclear
translocation (Figure 3E, F, p < 0.01).
Ca
2+ and Na
+ channel blockers inhibit the oxalate-induced
increase of TRPM8 mRNA levels in cultured DRG cells
Mexiletine (1 mM), nifedipine (30 μM) and diltiazem
(30 μM) reversed the increase in TRPM8 mRNA levels
induced by oxalate (500 μM, 12 h) (Figure 4, mexiletine
Figure 1 The incidence of cold hyperalgesia (A) and expression of TRPM8 (B-E) following oxaliplatin or sodium oxalate treatment.
Oxaliplatin (4 mg/kg) or sodium oxalate (1.3 mg/kg) was administered i.p. on days 1 and 2. A: The acetone test was performed on days 0, 3, 5,
8 and 15. B: On day 5 the rat L4-6 DRG treated with oxaliplatin was harvested and the mRNA expression of TRPM8 and G3PDH were
determined by PCR. C: On day 5 the rat L4-6 DRG treated with sodium oxalate was harvested and the protein of TRPM8 and b-actin were
determined by Western boltting. D, E: 500 μM of oxaliplatin (D) or sodium oxalate (E) was administered to cultured DRG cells for 3, 6 or 12 h.
mRNA expression of TRPM8 and G3PDH was determined by PCR. Values are expressed as the mean ± SEM of 4-6 animals (A, B) or 4-6 wells (C,
D). *p < 0.05, **p < 0.01 compared with vehicle or control group.
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2+ following oxaliplatin or oxalate treatment in primary cultured DRG cells. Oxaliplatin (A:1 0 0 -
500 μM) or sodium oxalate (B: 100-500 μM) was administered to cultured DRG cells. Nifedipine (C: 10-30 μM), diltiazem (D: 10-30 μM),
ethosuximide (E: 1 mM) or mexiletine (F: 100 μ-1 mM) were co-administered with sodium oxalate (500 μM) to cells. Intracellular Ca
2+ levels were
determined based on Fura-2 fluorescence (340 nm/380 nm). Values are expressed as the mean of 4-8 wells.
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Page 5 of 10Figure 3 NFAT nuclear translocation in primary cultured DRG cells. Oxaliplatin (A, B: 500 μM for 1-6 h) or sodium oxalate (C, D: 500 μM for
1-6 h) was administered to cultured DRG cells. E, F: Mexiletine (Mex, 1 mM), nifedipine (Nif, 30 μM), diltiazem (Dil, 30 μM) or vivit (2 μM) was co-
administered with sodium oxalate (500 μM) to cells for 6 h. NFATc4 immunostaining (green) and nuclear staining with DAPI (blue). NFATc4 and
DAPI-positive nuclei were visualized by fluorescence microscopy (A, C, E). The nuclear translocation of NFATc4 was calculated by comparing the
ratio of nuclear NFATc4 immunofluorescence/total NFATc4 immunofluorescence (B, D, F). Values are expressed as the mean ± SEM of 24-33 cells.
††p < 0.01 compared with control group, **p < 0.01 compared with oxalate group.
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vivit (2 μM) completely reversed the oxalate-induced
increase in TRPM8 mRNA levels (p < 0.01).
Ca
2+ and Na
+ channel blockers inhibit the oxaliplatin-
induced cold hyperalgesia and increase in TRPM8 mRNA
levels in the DRG in rats
Co-administration with nifedipine (10, 30 mg/kg, p.o.)
completely inhibited the oxaliplatin-induced increase in
withdrawal responses to acetone spray in rats (Figure 5A,
p < 0.01). Diltiazem (10, 30 mg/kg, p.o.) also strongly
inhibited the oxaliplatin-induced increase in withdrawal
responses (Figure 5B, p < 0.01). Similarly, mexiletine (10,
30 mg/kg, p.o.) attenuated the oxaliplatin-induced
increase in withdrawal responses (Figure 5D, p < 0.01).
By contrast, ethosuximide (300 mg/kg, p.o.) only weakly
prevented the oxaliplatin-induced increase in withdrawal
responses (Figure 5C, days 3 and 8: p < 0.05). Moreover,
co-administration with mexiletine (30 mg/kg, p.o.), nifedi-
pine (30 mg/kg, p.o.) or diltiazem (30 mg/kg, p.o.) com-
pletely inhibited the oxaliplatin-induced increase in
TRPM8 mRNA levels on day 5 (Figure 6, p < 0.01).
Discussion
Oxaliplatin was previously reported to induce cold allo-
dynia and increase in TRPM8 mRNA levels in the DRG
after 3 days in mice [16] and increase the TRPM8
mRNA levels in cultured rat DRG cells [19]. Consistent
with these reports, in the present study we demon-
strated that oxaliplatin induced cold hyperalgesia in rats
on days 3, 5 and 8 and increased the TRPM8 mRNA
levels in the DRG on day 5, the peak of cold hyperalge-
sia. Furthermore, we found that oxalate significantly
induced the increase in TRPM8 protein in the DRG on
day 5. In addition, we confirmed that oxaliplatin mark-
edly increased the TRPM8 mRNA levels in primary cul-
tured DRG cells.
TRPM8 is known to be involved in cold sensitivity [20]
and cold allodynia after chronic nerve injury [21]. More-
over, TRPM8-deficient mice attenuate behavioral response
to cold stimulation [22,23]. Oxaliplatin-induced cold allo-
dynia is reversed by capsazepine, a blocker of both
TRPM8 and TRP vanilloid 1 (TRPV1), but not by 5’-iodor-
esiniferatoxin, a selective TRPV1 blocker [16]. Hence, the
increase in TRPM8 expression in DRG neurons may be
involved in oxaliplatin-induced cold hyperalgesia. Recently,
Nassini et al. [24] have reported that oxaliplatin induces
mechanical and cold allodynia via TRP ankyrin 1 (TRPA1)
activation in rodents. Considering these collective findings,
both up-regulation of TRPM8 and activation of TRPA1
may be involved in the cold hypersensitivity by oxaliplatin.
We also found that treatment with oxalate, a metabolite of
oxaliplatin, markedly increased the TRPM8 mRNA levels
in primary cultured DRG cells. Furthermore, oxalate sig-
nificantly induced the increase in TRPM8 protein in the
DRG. Oxaliplatin is rapidly metabolized to Pt(dach)Cl2 in
rat blood in vitro [25], suggesting that oxalate is immedi-
ately derived from oxaliplatin. We previously reported that
oxalate induced cold hyperalgesia/allodynia but not
mechanical allodynia in rats [7]. Taken together, these
data suggest that oxalate may be involved in the oxalipla-
tin-induced increase in TRPM8 expression, resulting in
cold hyperalgesia.
In the present study, both oxaliplatin and oxalate
increased the intracellular Ca
2+ levels in primary cul-
tured DRG cells, and the oxalate-induced increase in
intracellular Ca
2+ level was inhibited by nifedipine (an L
type Ca
2+ channel blocker) and diltiazem (an L/T type
Ca
2+ channel blocker). By contrast, ethosuximide (a T
type Ca
2+ channel blocker) only weakly attenuated the
oxalate-induced increase in intracellular Ca
2+. Thus, it is
likely that oxaliplatin induces Ca
2+ influx via mainly L
type Ca
2+ channels. Oxaliplatin was reported to increase
the amplitude and duration of compound action poten-
tials interacting with voltage-gated Na
+ channels in rat
sensory neurons [9], and prolong the duration of the A-
fiber compound action potential related to K
+ channels
[12]. Thus, enhancement of action potentials via Na
+ or
K
+ channels might result in Ca
2+ influx through L type
Ca
2+ channels. This mechanism is supported by the
Figure 4 Reversal of the oxalate-induced increase in TRPM8
mRNA in cultured DRG cells by Ca
2+ and Na
+ channel blockers.
Mexiletine (Mex, 1 mM), nifedipine (Nif, 30 μM), diltiazem (Dil, 30
μM) or vivit (2 μM) was co-administered with sodium oxalate (500
μM) to cells for 12 h. The mRNA expression of TRPM8 and G3PDH
were determined by PCR. Values are expressed as the mean ± SEM
of 6 wells. ††p < 0.01 compared with control group, *p < 0.05, **p
< 0.01 compared with oxalate group.
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+ channel blocker mexiletine
completely reversed the oxalate-induced Ca
2+ influx.
In general, NFAT is activated and translocated into the
nucleus via Ca
2+ signaling [26]. In the present study, both
oxaliplatin and oxalate induced the nuclear translocation
of NFAT in cultured DRG cells, and the oxalate-induced
NFAT nuclear translocation was completely blocked by
nifedipine, diltiazem and mexiletine, as well as vivit, a
selective NFAT inhibitor. Furthermore, nifedipine, diltia-
zem, mexiletine and vivit reversed the oxalate-induced
increase in TRPM8 mRNA levels in cultured DRG cells.
Taken together, these data suggest that oxalate may
induce up-regulation of TRPM8 expression via NFAT
activation by Ca
2+ influx through L/T type Ca
2+ channels
derived from Na
+ channels activation. We also confirmed
that co-administration with nifedipine, diltiazem or mexi-
letine inhibited the oxaliplatin-induced cold hyperalgesia
and increase in TRPM8 mRNA levels in the DRG in vivo
in rats. Thus, the oxaliplatin-induced cold hyperalgesia is
mediated by up-regulation of TRPM8 expression via Na
+
and Ca
2+ influx.
In addition, Fajardo et al. [27] have reported that L-
type Ca
2+ channel blockers 1,4-dihydropyridines such as
nifedipine activate TRPA1-mediated currents in CHO
cells in electrophysiological study. However, they reported
that no signs of behavioral pain were observed following
local application of nifedipine to the hind paw of mice.
Because nifedipine blocks electrically evoked Ca
2+ transi-
ents in peripheral sensory nerves [28], it is possible that
these potent inhibitory actions on L-type Ca
2+ channels
prevent the propagation of electrical impulses at nerve
terminals, despite a powerful TRPA1 activation.
Conclusions
We demonstrated that L type Ca
2+ channel/NFAT/
TRPM8 pathway plays a crucial role in signaling the
Figure 5 Reversal of the oxaliplatin-induced cold hyperalgesia in rats by Ca
2+ and Na
+ channel blockers. Oxaliplatin (4 mg/kg) was
administered i.p. on days 1 and 2. Nifedipine (A: 10 and 30 mg/kg), diltiazem (B: 10 and 30 mg/kg), ethosuximide (C: 100 and 300 mg/kg) or
mexiletine (D: 3-30 mg/kg) was orally co-administered with oxaliplatin. Acetone test was performed on days 0, 3, 5, 8 and 15. Values are
expressed as the mean ± SEM of 6-10 animals. ††p < 0.01 compared with vehicle group, *p < 0.05, **p < 0.01 compared with oxaliplatin group.
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of L type Ca
2+ channel blockers inhibited the oxalipla-
tin-induced cold hyperalgesia. Therefore, novel strategies
involving Ca
2+ channel blockers may be useful for pre-
vention of oxaliplatin-induced acute neuropathy.
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